VK2735 (5mg/10mg)
Viking Therapeutics' Dual GLP-1 / GIP Receptor Agonist
VK2735 is listed for GIP and GLP-1 research. Catalog vial contents are 5mg / 10mg; select the required strength before ordering. This material is supplied for Research Use Only, not as a medicine or a product for human or veterinary use.
Research Applications & Benefits
- Dual GLP-1 + GIP receptor activation
- Subcutaneous and oral formulations under development
- Rapid early-phase weight-loss kinetics
- Comparator to tirzepatide in research models
What is VK2735?
VK2735 is an investigational peptide with GIP and GLP-1 receptor activity. The catalog offers 5mg and 10mg research vials. A shared receptor class does not make it identical to tirzepatide.
Listed vial contents: 5mg / 10mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.
What mechanisms are being studied?
Researchers examine activation of both incretin receptors and compare responses in matched assays. The supplied sequence and chemical modifications must be established before attributing a clinical candidate's behavior to inventory.
What are the research questions?
- GIP and GLP-1 receptor responses
- Sequence-specific comparisons among dual agonists
- Understanding short-duration trial endpoints
What does the published work describe?
Bays and colleagues' VENTURE publication describes a randomized phase 2 trial with 13 weeks of treatment. It evaluated a defined VK2735 clinical formulation in adults with obesity or overweight. A short-duration trial does not establish long-term outcomes or equivalence to this research vial.
Experimental models in the cited papers
- VENTURE: randomized, placebo-controlled phase 2 human trial
What could future research explore?
Further work can compare dual-receptor responses and longer-term clinical endpoints. Direct comparator studies are needed before making superiority claims against other incretin compounds.
These are research directions, not established applications of the product sold here.
What are the limits of this evidence?
Clinical findings apply to the tested formulation, trial population and study conditions. They do not establish the identity, safety or effectiveness of this laboratory vial. Research Use Only: this material is not a finished medicine.
Study references
- Bays HE, et al. Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. Obesity (Silver Spring). 2026. PMID 41508550
How should I check lot documentation?
Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. A report is evidence only for the product, strength and lot it names.
How is VK2735 handled in the lab?
For VK2735, record the product code VK27-10, selected strength and lot before opening. Follow the material-specific safety data sheet and laboratory SOP, with appropriate gloves, eye protection and containment. For a documented dry preparation, let the sealed vial equilibrate before opening to reduce condensation; minimize time open and use clean, compatible vessels.
Choose a solvent for VK2735 from the documented sequence or chemical identity, salt form and assay requirements. Test a small portion first and record pH, solvent composition and clarity. Do not assume one diluent works for every research material; include a solvent-only control and establish compatibility before using the stock in an assay. For a documented lipid-modified construct, evaluate aggregation and adsorption as well as apparent solubility; check compatibility again after dilution into the final assay buffer.
For VK2735, calculate mass concentration as measured material mass divided by final solution volume. Calculate molarity only with a documented molecular weight for the supplied chemical form; the catalog lists ~4500 g/mol as a reference, not lot confirmation. Where available, use matched-lot net content rather than treating chromatographic purity as a mass correction. Record both stock concentration and subsequent dilution factors.
Use the documented storage conditions for the supplied VK2735 form and lot. For a documented lyophilized preparation, keep the vial sealed and protected from moisture; for solutions, validate temperature, light exposure and holding time in the assay. Use compatible single-use aliquots when appropriate to reduce repeated freeze-thaw. No universal temperature or 28-day solution shelf life is established by the catalog name.
A VK2735 laboratory protocol should record identity, product code VK27-10, strength, lot, applicable analysis results, solvent and pH, stock concentration, dilution sequence, vessel type, storage history and assay endpoints. Include vehicle and reference controls, independent replicates and predefined acceptance criteria. Separate handling validation from biological interpretation; these notes do not provide administration or dosing instructions.
Research Use Only. Not for human consumption, therapeutic, veterinary or any in-vivo use.
Product Specifications
- Compound
- VK2735
- CAS Number
- 2702966-26-5
- Molecular Weight
- ~4500 g/mol
- HPLC Purity Specification
- ≥99%
- Category
- GLP-1 & Metabolic
- Starting Price
- $169.00 USD
- Country of Origin
- United States
- Shipping
- Cold-chain insulated packaging, fast domestic delivery
- Payment
- Card, ACH, and cryptocurrency (10% discount)
Quality & Verification
VK2735 has a catalog purity specification of ≥99%; this is not a measured result for every vial. Match the product, exact strength, batch and lot to its analysis record and read only the reported fields. HPLC peak-area purity, measured content and endotoxin are separate measurements. A blank field means no result is reported, not zero or passed. A purity percentage alone does not establish identity, sterility or suitability for human use.
Frequently Asked Questions
What is VK2735?
VK2735 is listed for GIP and GLP-1 research. Catalog vial contents are 5mg / 10mg; select the required strength before ordering. This material is supplied for Research Use Only, not as a medicine or a product for human or veterinary use.
What strengths of VK2735 are available?
The catalog lists 5mg / 10mg. These labels describe vial contents, not administration doses. Select the required strength for current pricing and availability; match analysis records to that exact strength and lot.
How should I interpret VK2735 purity results?
VK2735 has a catalog purity specification of ≥99%; this is not a measured result for every vial. Match the product, exact strength, batch and lot to its analysis record and read only the reported fields. HPLC peak-area purity, measured content and endotoxin are separate measurements. A blank field means no result is reported, not zero or passed. A purity percentage alone does not establish identity, sterility or suitability for human use.
How should VK2735 be handled in the laboratory?
For VK2735, record the product code VK27-10, selected strength and lot before opening. Follow the material-specific safety data sheet and laboratory SOP, with appropriate gloves, eye protection and containment. For a documented dry preparation, let the sealed vial equilibrate before opening to reduce condensation; minimize time open and use clean, compatible vessels.
How do I choose a laboratory solvent for VK2735?
Choose a solvent for VK2735 from the documented sequence or chemical identity, salt form and assay requirements. Test a small portion first and record pH, solvent composition and clarity. Do not assume one diluent works for every research material; include a solvent-only control and establish compatibility before using the stock in an assay. For a documented lipid-modified construct, evaluate aggregation and adsorption as well as apparent solubility; check compatibility again after dilution into the final assay buffer.
How do I calculate a VK2735 stock concentration?
For VK2735, calculate mass concentration as measured material mass divided by final solution volume. Calculate molarity only with a documented molecular weight for the supplied chemical form; the catalog lists ~4500 g/mol as a reference, not lot confirmation. Where available, use matched-lot net content rather than treating chromatographic purity as a mass correction. Record both stock concentration and subsequent dilution factors.
How should VK2735 be stored after preparation?
Use the documented storage conditions for the supplied VK2735 form and lot. For a documented lyophilized preparation, keep the vial sealed and protected from moisture; for solutions, validate temperature, light exposure and holding time in the assay. Use compatible single-use aliquots when appropriate to reduce repeated freeze-thaw. No universal temperature or 28-day solution shelf life is established by the catalog name.
What should a VK2735 lab protocol document?
A VK2735 laboratory protocol should record identity, product code VK27-10, strength, lot, applicable analysis results, solvent and pH, stock concentration, dilution sequence, vessel type, storage history and assay endpoints. Include vehicle and reference controls, independent replicates and predefined acceptance criteria. Separate handling validation from biological interpretation; these notes do not provide administration or dosing instructions.
Does Fmoc or Boc synthesis explain this VK2735 product?
Fmoc and Boc are peptide protecting-group strategies, not proof of how this VK2735 lot was made. For sequence-defined peptides, synthesis review can examine deletion products, incomplete deprotection and modifications using the method and matching analytical evidence. A single chromatographic peak does not by itself establish sequence.
Is VK2735 for human use?
No. VK2735 is strictly Research Use Only. It is not intended for human or veterinary use, diagnosis or treatment. Laboratory handling guidance is not an administration protocol.
Research Use Only. This product is intended for licensed laboratory research and is not for human or veterinary use.
